CRONOS GROUP INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings
CRONOS GROUP INC. (CRON) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings of $49.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings · last filed 2025-02-27
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2023-12-31 was -$71.00K.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2023-09-30 was $8.00K, a 97.87% decline year-over-year.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2023-06-30 was $43.00K, a 98.74% decline year-over-year.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2023-03-31 was -$65.00K, a 100.62% decline year-over-year.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2024 was $49.00K.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2023 was -$85.00K, a 100.60% decline from fiscal 2022.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2022 was $14.06M, a 90.71% decline from fiscal 2021.
- CRONOS GROUP INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2021 was $151.36M, a 17.10% increase from fiscal 2020.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 10 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $49.00K 10-K · filed 2025-02-27 | ||||
| 2023-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$63.00K derived: sum of 2 quarters · filed 2025-02-27 | -$20.00K derived: sum of 3 quarters · filed 2025-02-27 | -$85.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $8.00K 10-Q · filed 2023-11-08 | $51.00K derived: sum of 2 quarters · filed 2023-11-08 | -$14.00K 10-Q · filed 2023-11-08 | -$158.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2023-06-30 | $43.00K 10-Q · filed 2023-08-08 | -$22.00K 10-Q · filed 2023-08-08 | -$166.00K derived: sum of 3 quarters · filed 2024-02-29 | $209.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2023-03-31 | -$65.00K 10-Q · filed 2023-05-09 | -$209.00K derived: sum of 2 quarters · filed 2024-02-29 | $166.00K derived: sum of 3 quarters · filed 2024-02-29 | $3.58M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $231.00K derived: sum of 2 quarters · filed 2024-02-29 | $3.64M derived: sum of 3 quarters · filed 2024-02-29 | $14.06M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $375.00K 10-Q · filed 2023-11-08 | $3.79M derived: sum of 2 quarters · filed 2023-11-08 | $14.20M 10-Q · filed 2023-11-08 | $34.27M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $3.41M 10-Q · filed 2023-08-08 | $13.83M 10-Q · filed 2023-08-08 | $33.90M derived: sum of 3 quarters · filed 2023-08-08 | $166.81M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $10.42M 10-Q · filed 2023-05-09 | $30.49M derived: sum of 2 quarters · filed 2023-05-09 | $163.41M derived: sum of 3 quarters · filed 2023-05-09 | $278.65M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $20.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $152.99M derived: sum of 2 quarters · filed 2023-02-28 | $268.23M derived: sum of 3 quarters · filed 2023-02-28 | $151.36M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $132.92M 10-Q · filed 2022-11-07 | $248.16M derived: sum of 2 quarters · filed 2022-11-07 | $131.29M 10-Q · filed 2022-11-07 | $77.75M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $115.25M 10-Q · filed 2022-08-09 | -$1.63M 10-Q · filed 2022-08-09 | -$55.17M derived: sum of 3 quarters · filed 2022-08-09 | $50.14M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$116.87M 10-Q · filed 2022-05-10 | -$170.41M derived: sum of 2 quarters · filed 2022-05-10 | -$65.11M derived: sum of 3 quarters · filed 2022-05-10 | -$100.99M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$53.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $51.77M derived: sum of 2 quarters · filed 2022-03-01 | $15.89M derived: sum of 3 quarters · filed 2022-03-01 | $129.25M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $105.31M 10-Q · filed 2022-02-18 | $69.43M derived: sum of 2 quarters · filed 2022-02-18 | $182.79M 10-Q · filed 2022-02-18 | ||
| 2020-06-30 | -$35.88M 10-Q/A · filed 2022-02-18 | $77.49M 10-Q/A · filed 2022-02-18 | |||
| 2020-03-31 | $113.37M 10-Q · filed 2021-05-07 | ||||
| 2019-12-31 | $1.28B 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |